Abstract
Objective
To evaluate oral pre-exposure prophylaxis (PrEP) uptake, retention and adherence among female sex workers (FSWs) receiving care through community and facility delivery models in sub-Saharan Africa (SSA).
Design
Systematic review and meta-analysis.
Data sources
We searched online databases (PubMed, MEDLINE, SCOPUS, EMBASE, Google Scholar, Cochrane Database of Systematic Reviews and Web of Science) between January 2012 and 3 April 2022.
Eligibility criteria for studies
Randomised controlled trials, cohort studies, cross-sectional studies and quasi-experimental studies with PrEP uptake, adherence and retention outcomes among FSWs in SSA.
Data extraction and synthesis
Seven coders extracted data. The framework of the Cochrane Consumers and Communication Review Group guided data synthesis. The Risk of Bias In Non-Randomized Studies of Interventions tool was used to evaluate the risk of bias. Meta-analysis was conducted using a random-effects model. A narrative synthesis was performed to analyse the primary outcomes of PrEP uptake, adherence and retention.
Results
Of 8538 records evaluated, 23 studies with 40 669 FSWs were included in this analysis. The pooled proportion of FSWs initiating PrEP was 70% (95% CI: 56% to 85%) in studies that reported on facility-based models and 49% (95% CI: 10% to 87%) in community-based models. At 6 months, the pooled proportion of FSWs retained was 66% (95% CI: 15% to 100%) for facility-based models and 83% (95% CI: 75% to 91%) for community-based models. Factors associated with increased PrEP uptake were visiting a sex worker programme (adjusted OR (aOR) 2.92; 95% CI: 1.91 to 4.46), having ≥10 clients per day (aOR 1.71; 95% CI: 1.06 to 2.76) and lack of access to free healthcare in government-run health clinics (relative risk: 1.16; 95% CI: 1.06 to 1.26).
Conclusions
A hybrid approach incorporating both facility-based strategies for increasing uptake and community-based strategies for improving retention and adherence may effectively improve PrEP coverage among FSWs.
PROSPERO registration number
CRD42020219363.
Keywords: epidemiology, HIV & AIDS, health policy, systematic review, behavior, health services
STRENGTHS AND LIMITATIONS OF THIS STUDY.
This systematic review provides meta-analyses of pre-exposure prophylaxis (PrEP) uptake, retention and adherence among female sex workers (FSWs) in sub-Saharan Africa who accessed PrEP through community and facility delivery models.
Our review was limited because we included non-randomised controlled trial study designs to evaluate the effect of PrEP delivery models on our outcomes.
Some of the studies included in this review focused on key populations in general and had small samples of FSWs.
This review was limited to evaluating oral PrEP uptake, retention and adherence for cisgender FSWs accessing community or facility PrEP delivery models.
Introduction
Female sex workers (FSWs) have a 30 times greater risk of acquiring HIV than other women aged 15–49 years in the general population.1 In sub-Saharan Africa (SSA), sex workers and sex partners of key populations account for 15% and 26% of new HIV infections, respectively.1 The Joint United Nations Programme on HIV/AIDS (UNAIDS) global target is for 95% of people at risk of HIV to use person-centred and effective combination prevention methods by 2025.2 HIV pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by people without HIV to prevent HIV acquisition.3 The WHO recommends multiple PrEP options (daily pill, monthly dapivirine vaginal ring or 2-month injectable cabotegravir) as part of combination prevention approaches for people at substantial risk of HIV infection.4 However, FSWs in SSA have suboptimal PrEP uptake, adherence and retention5–8 despite significant HIV risk.
The WHO also recommends decentralised, simplified and differentiated service delivery to support PrEP uptake, continuation and effective use.9 The WHO building blocks of differentiated PrEP service delivery are (1) where to deliver PrEP (service location: health facility or community); (2) who to deliver PrEP (service provider: physician, clinical officer, nurse, pharmacist, community health worker or peer); (3) when to deliver PrEP (service frequency: monthly, quarterly, every 6 months); and (4) what to deliver (service package: HIV testing, PrEP refills, condoms, lubricant, contraception).10 Diversifying PrEP delivery increases choice of service location, provider and PrEP formulation and overcomes barriers to PrEP access.5
FSWs face a range of barriers when accessing PrEP through healthcare facilities; thus, diversifying where PrEP is delivered could increase PrEP access for this stigmatised population.9 Whereas differentiated PrEP service delivery is effective for men who have sex with other men, adolescent girls and young women,11 12 evidence of the effect of service location on PrEP-related outcomes (uptake, retention, adherence) for FSWs in SSA is needed. We conducted a systematic review to compare PrEP uptake, retention and adherence among African FSWs receiving PrEP delivered through community or facility-based models.
Methods
This systematic review was developed and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols 2020 statement.13 The protocol was registered with PROSPERO (https://www.crd.york.ac.uk/prospero/; registration number: CRD42020219363).
Eligibility criteria
Types of studies
This review included randomised controlled trials, cohort studies, cross-sectional studies and quasi-experimental studies in original research articles published in peer-reviewed journals and the grey literature, with PrEP uptake, adherence and retention outcomes among FSWs in SSA and India. We excluded qualitative studies (4676), publications from resource-rich settings (1037), studies of populations other than FSWs (527) and non-English articles (102).
Types of participants
Participants were FSWs aged 14 years and older, HIV negative and taking PrEP.
Types of intervention
The interventions included PrEP facility and community delivery models. A control group was not included because this study aimed to compare PrEP uptake, retention and adherence between different delivery models.
Types of outcome measures
Primary outcomes
Primary outcomes were PrEP uptake, retention and adherence among FSWs by delivery model. Uptake was defined as PrEP initiation during the review period. Retention was defined as remaining in PrEP care for at least 6 months. Adherence was defined as taking PrEP as prescribed during the study period through various delivery strategies.
Secondary outcomes
Secondary outcomes were demographic and clinical factors associated with PrEP uptake, retention and adherence among FSWs.
Search strategy
An experienced information scientist performed a thorough literature search on the following bibliographical databases: PubMed (biomedical, 1946–present, https://www.ncbi.nlm.nih.gov/pubmed/), Google Scholar (multidisciplinary, https://scholar.google.com/), SciVerse SCOPUS (multidisciplinary, 1823–present, https://www.scopus.com/) and EMBASE-OVID (biomedical, 1947–present, https://www.embase.com). Additional grey literature searches were manually performed on the UNAIDS database (https://www.unaids.org/en), WHO (https://www.who.int/) and the National Institutes of Health (NIH) websites (https://www.nih.gov). Furthermore, a citation search was conducted using references and citations from the included studies and similar systematic reviews.
The search strategy was developed and piloted for sensitivity and specificity to ensure the comprehensiveness and inclusivity of all relevant literature. PubMed served as the primary database for this process. The search was limited to original primary research articles published in peer-reviewed journals and unpublished studies from institutional websites and repositories from 2012 to 3 April 2022, following the Population, Intervention, Control, Outcomes, Study design and Time frame format.14 The following key search terms—HIV/AIDS, female sex workers, pre-exposure prophylaxis, delivery models, PrEP uptake, adherence and retention—were combined using Boolean operators (AND, OR, NOT) during the information search. The search was restricted to articles written in English or had an accompanying English translation.
Data collection process
Eligibility criteria
Our search was limited to original articles from primary studies published in peer-reviewed journals and unpublished studies found on institutional websites and repositories. This search covered the period between 1 January 2012 and 3 April 2022. The criteria for inclusion in this review required all articles to be written in English or have an English translation. This ensured that only relevant studies were retrieved and considered for this review. The retrieved studies were imported into EndNote V.X9.3.3 (Clarivate Analytics, Philadelphia, USA) using the program’s duplicate management features to eliminate duplicate entries and create a comprehensive and organised citation database. This database was exported to Microsoft Excel V.2016 (Microsoft Corporation, Redmond, Washington, USA) for title and abstract screening.
The screening tool was created and tested using a subset of 10% of the collected studies to encompass all elements of the eligibility criteria. Articles were screened based on their title and abstract; subsequently, those that met the eligibility criteria were subjected to full-text screening.
Study selection process/screening
Pairs of research assistants conducted the screening process. Any discrepancies were resolved and subsequently verified by author RM to ensure accuracy. Rescreening and retraining were performed if the level of agreement between RM, IS and KOO was <80%. Decisions and justifications for the exclusion of studies were duly recorded. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart was used to summarise the selection process (figure 1).
Figure 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart. FSW, female sex worker; LMIC, low/middle-income country; NIH, National Institutes of Health; UNAIDS, Joint United Nations Programme on HIV/AIDS.
Data abstraction process/coding
The coding tool was developed and pilot-tested to guarantee the inclusion of all necessary data elements for this review, using Microsoft Excel V.2016 (Microsoft Corp, Redmond, Washington, USA) for abstraction purposes. The coding process was carried out by pairs of individuals on the review team, and any discrepancies were resolved through discussion after reconciling their respective results. An independent senior reviewer validated the results for quality control and assurance.
Data items
The primary outcomes for this systematic review were FSW uptake, retention and adherence to PrEP in both community and facility delivery models. Secondary outcomes were barriers and enablers of FSW PrEP uptake, adherence and retention in community and facility PrEP delivery models. We also collected administrative details such as author name, year of publication and author’s affiliation, along with data on study design and delivery model components (online supplemental table 1).
bmjopen-2023-076545supp001.pdf (366.7KB, pdf)
bmjopen-2023-076545supp006.pdf (125.4KB, pdf)
bmjopen-2023-076545supp005.pdf (127.4KB, pdf)
bmjopen-2023-076545supp003.pdf (139.1KB, pdf)
bmjopen-2023-076545supp002.pdf (328.1KB, pdf)
bmjopen-2023-076545supp004.pdf (139.2KB, pdf)
Assessment of risk of bias in the included studies
The risk of bias in each included study was evaluated by two independent reviewers (IS and KOO) using the Risk of Bias In Non-Randomized Studies of Interventions tool. The risk of bias assessment covered several domains, including bias due to confounding, bias in selection of participants into the study, bias in the classification of interventions, bias due to deviations from intended observations, bias due to missing data and bias in the selection of reported studies. Differences between reviewers were discussed until a consensus was reached.
Measure of PrEP delivery model effect
We reported pooled proportions of PrEP uptake (online supplemental figure 1) and retention (online supplemental figure 2) as reported by the study authors. Due to the lack of homogeneity among the included studies (p=0.31), conducting a meta-analysis to generate more accurate point estimates for the facility and community PrEP delivery models was not feasible.
Missing data
The included studies did not report any missing data. The author was contacted via email if further clarification regarding the provided data was necessary.
Assessment of publication bias
The Doi plot and Luis Furuya-Kanamori asymmetry index (LFK index) were used to evaluate the presence of publication bias. If there is symmetry, no publication bias exists, whereas a lack of symmetry may suggest the presence of publication bias. An LFK index of ±1 indicates no asymmetry, an LFK index between ±1 and ±2 represents minor asymmetry, and an LFK index greater than ±2 signifies major asymmetry. The Doi plot for publication bias showed no signs of symmetry, confirming the presence of bias (online supplemental figures 3 and 4).
Heterogeneity
A random-effects model was used for the meta-analysis, with heterogeneity among studies evaluated visually through a forest plot and quantitatively using the I2 index. The heterogeneity threshold was set at I2≥50%. Overall, there was significant variability in PrEP uptake (I2=99.9%) across studies, as reflected by the random-effects pooled proportion estimate of 63% (95% CI: 48% to 79%). Regarding retention in care, the findings indicate significant heterogeneity among studies (I2=99.9%), with an overall pooled retention rate of 76% (95% CI: 55% to 97%). Our meta-analysis revealed significant heterogeneity among studies regarding PrEP uptake and retention rates. However, the small number of studies prevented us from conducting in-depth analysis using meta-regression.
Data synthesis
The data synthesis process adhered to the structure prescribed by the Cochrane Consumers and Communication Review Group.15 We described the included articles, categorised them by study design and intervention type, systematically organised and tabulated findings to discern trends, and standardised the results into a unified descriptive format. The data were integrated into the summary of findings tables, which informed the syntheses used for dissemination. A narrative synthesis was performed to analyse the primary outcomes of PrEP uptake, adherence and retention among FSWs in community and facility delivery models.
Statistical analysis
The data were analysed using a restricted maximum likelihood model. The primary features of the included studies were consolidated by calculating pooled proportions to estimate overall PrEP uptake, retention and adherence for both community and facility PrEP delivery models. Pooled proportions with exact binomial 95% CIs were calculated and presented in forest plots (online supplemental figures 1 and 2). The homogeneity of results was calculated using the Χ2 test, while the I2 statistic was used to describe the percentage variation across included studies. All analyses were performed using STATA V.16.0 (StataCorp, Stata Statistical Software: College Station, Texas, USA).
Patient and public involvement
The PrEP technical team at the School of Medicine, Makerere University, Uganda provided feedback on the review protocol and analysis. FSWs were involved in a qualitative study, and the Ugandan Ministry of Health may ultimately consider their stated preferences while developing PrEP delivery guidelines.
Results
Identification and selection of studies
A total of 8538 citations were retrieved after searching bibliographical databases (Google Scholar, EMBASE-OVID, PubMed, SCOPUS) and institutional websites (WHO, UNAIDS and NIH). After the removal of duplicates, 6952 citations remained. Of these, 6433 articles were excluded after title and abstract screening. The remaining 519 full-text articles were screened for eligibility, of which 23 articles were included for data abstraction. An additional 10 articles were included from reference searching, yielding a total of 33 articles for coding (figure 1).
Characteristics of excluded studies
Out of the 8538 records identified, 1582 duplicates were removed. Of the remaining 6956 records, 6433 studies were excluded at title and abstract screening because they had an inappropriate study design (4767), were not in low/middle-income countries (LMICs) (1037), not among FSWs (527) and were not written in English (102). The remaining 523 articles were assessed for eligibility using full text, of which 496 were excluded because they lacked relevant outcomes (278), had inappropriate study design (151), were not among FSWs (38), were from high-income countries (24) or were not written in English (7) (figure 1).
Characteristics of included studies
Of the 23 articles included in the data abstraction, 21 were from SSA (Benin, Democratic Republic of Congo, Eswatini, Ghana, Ivory Coast, Kenya, Senegal, South Africa, Uganda and Zimbabwe) and 2 were from South Asia (India) (table 1). Five studies were conducted in South Africa. All studies were published in peer-reviewed journals between 2016 and 2022. Reviewed studies included 40 699 participants (median: 647, IQR: 1928) and ranged in size from 126 (smallest study) to 19 407 (largest study) participants. 16 studies were cohort studies, demonstration projects, randomised trials or mixed-methods studies, and 7 were cross-sectional. 14 articles described facility-based delivery models, 8 studies used community models and 1 study did not report the delivery model.
Table 1.
Study characteristics
| Study ID | Country | Study design | Sample size | Delivery model | Unique model components |
| Rao (2022) | South Africa | Retrospective cohort | 2776 | Facility based | NR |
| Witte et al 31 | Uganda | Cross-sectional | 542 | Community based | Hotspots |
| Hensen et al 19 | Zimbabwe | Mixed methods | 963 | Facility based | Static clinics, community mobilisation and referrals (DREAMS Initiative) |
| Jana et al 24 | India | Demonstration trial | 678 | Home delivery & facility based | Weekly pick-ups and home delivery |
| Little et al 33 | South Africa | Mixed methods | 600 | Facility based | Training of staff and peers |
| Leis et al 22 | Kenya | Cross-sectional | 220 | Facility based | Availability of free PrEP |
| Franks et al 21 | DRC | Demonstration project | 469 | Facility based | Leveraged existing facility staff and was supported by the PrEP coordinator |
| Chimbindi (2021) | South Africa | Mixed methods | 2184 | Community based | Hotspots |
| Nalukwago (2021) | Uganda | Cross-sectional | 126 | Facility based | Drug pick-ups |
| Matambanadzo et al 30 | Zimbabwe | Follow-up study | 19 407 | Community based | Peer led, used virtual appointment platforms, had multimonth refills, post-initiation support, unique alphanumerical identifier |
| Kagaayi et al 26 | Uganda | Retrospective cohort | 1332 | Facility based | Health facilities and community outreach |
| Diantha (2020) | South Africa | Cross-sectional | 299 | Facility based | Implementers of oral PrEP |
| Sarr et al 25 | Senegal | Demonstration trial | 267 | Facility based | Clinic drug refills |
| Geldsetzer (2020) | Eswatini | Stepped-wedge RCT and qualitative survey | 2232 | Facility based | PrEP promotion using videos and T-shirts, flip charts and booklets |
| Becquet (2020) | Ivory Coast | Mixed methods | 1000 | Community based | Use of community-based organisations |
| Guure (2020) | Ghana | Cross-sectional | 998 | Community based | Venue, day and time scheduling at different FSW venues |
| Sushena (2020) | India | Demonstration trial | 647 | Community based | Intense community preparedness using peers and leaders |
| Mudzviti (2020) | Zimbabwe | Cross-sectional | 131 | NR | NR |
| Chimbindi (2019) | South Africa | Cohort | 2184 | Community based | Targeted rollout (demand for, access to and community members’ attitude toward PrEP) |
| Mboup et al 27 | Benin | Prospective cohort | 256 | Facility based | Drug refills at the facility and in the community, integration of ART with PrEP |
| Cowan et al 20 | Zimbabwe | Cluster randomised trial | 2883 | Facility based | Community mobilisation, legal advice, trained peers, drop-in centres and telephone reminders (Sister’s Programme) |
| Eakle et al 28 | South Africa | Retrospective cohort | 219 | Facility based | Clinic pick-ups |
| Alary (2016) | Benin | NR | 256 | Community based | NR |
ART, antiretroviral treatment; DRC, Democratic Republic of Congo; FSW, female sex worker; NR, not reported; PrEP, pre-exposure prophylaxis; RCT, randomised controlled trial.
Risk of bias in studies
Risk of bias assessment for the non-randomised studies16 included in the systematic review shows that the studies scored strongly across the six components considered in the evaluation. Among the included articles, only 8% reported withdrawals and dropouts from the study during the analysis. Some studies (21%) did not report the study design. Data collection methods and confounding were commonly mentioned in 100% of the studies (online supplemental figure 6). Funnel plots were not used to assess publication bias because they are not recommended for proportional meta-analyses.17 The Doi plot and LFK index were used to evaluate potential publication bias.18 An LFK index of ±1 indicates no asymmetry, an LFK index between ±1 and ±2 represents minor asymmetry, and an LFK index greater than ±2 signifies major asymmetry. The Doi plot for publication bias showed no signs of symmetry, confirming the presence of bias (online supplemental figures 3 and 4).
Sensitivity analysis
Sensitivity analysis excluded studies with significantly small or large effect sizes and a limited sample size. The LFK’s test results did not change substantially; therefore, the conclusions remained unchanged.
PrEP uptake
14 studies reported PrEP uptake,19–32 with varying definitions used among the studies (table 2). Nine (64%) defined uptake as the proportion of clients enrolled in PrEP care,20 21 24–27 30 32 two (14%) defined it as the proportion of clients who had ever used PrEP,19 22 and two (14%) defined uptake as currently using PrEP or having knowledge of PrEP. Overall, the pooled proportion of PrEP uptake was 63% (95% CI: 48% to 79%): 70% (95% CI: 56% to 85%) in facility-based models19 28 and 49% (95% CI: 10% to 87%) in community models29 31 (online supplemental figure 1). Factors associated with increased PrEP uptake included visiting a sex worker programme (adjusted OR (aOR) 2.92; 95% CI: 1.91 to 4.46), having ≥10 clients per day (aOR 1.71; 95% CI: 1.06 to 2.76)19 and lack of access to free public sector healthcare (relative risk 1.16; 95% CI: 1.06 to 1.26).25 Factors associated with decreased PrEP uptake included duration of sex work ≥2 years (aOR 0.51; 95% CI: 0.32 to 0.83) and experiencing emotional violence (aOR 0.23; 95% CI: 0.07 to 0.71).22 Reasons for initiating PrEP included sexual activity, perceived risk of HIV and having multiple sexual partners.23 PrEP decliners were concerned about daily intake of PrEP,21 23 side effects23 24 27 31 or stigma.23 31
Table 2.
PrEP uptake
| Study ID | Uptake | Definition of uptake | Factors associated with (or reasons for) PrEP uptake |
| Facility-based models | |||
| Hensen et al 19 | 33.6% | Ever used/total | FSWs with a high number (10+) of clients (aOR 1.71; 95% CI: 1.06 to 2.76), duration of sex work (<2 years, aOR 0.51; 95% CI: 0.32 to 0.83), having visited a sex worker programme in 12 months (aOR 2.92; 95% CI: 1.91 to 4.46) and ever been offered PrEP were more likely to initiate PrEP. |
| Cowan et al 20 | 38.4% | Enrolled/eligible | NR |
| Franks (2021) | NR | Enrolled/eligible | Decliners were not interested in daily medication and did not believe they needed PrEP*. |
| Leis et al 22 | 60.9% | Current or past user/total | Current PrEP users who experienced emotional violence (aOR 0.23; 95% CI:0.07 to 0.71) had a decline in PrEP use, while those who experienced physical violence (aOR 3.01; 95% CI: 1.16 to 7.81) increased their PrEP use. |
| Pillay et al 23 | 66.3% | Current or past users/those who have heard of PrEP | Reasons for accepting PrEP included being sexually active (34.5%), perceived risk of HIV (25.7%) and had multiple sex partners (23.9%), whereas for decliners failed side effects (41.9%), stigma (12.9%) and daily adherence (12.9%). |
| Jana et al 24 | 80.4% | Enrolled/eligible | Decliners found daily PrEP inconvenient (14%) and feared side effects (43%), while others gave no reason (14%) or did not identify as FSW (29%). |
| Sarr et al 25 | 82.4% | Enrolled/eligible | Unregistered FSWs (RR 1.16; 95% CI: 1.06 to 1.26) more likely to initiate. |
| Kagaayi et al 26 | 82.8% | Enrolled/eligible | NR |
| Mboup et al 27 | 88.3% | Enrolled/eligible | Decliners did not want to take daily pills (4/34), wanted to think more about PrEP (4/34), do not perceive self as at risk (9/34), were afraid of side effects (9/34) and were going out of town (8/34). |
| Eakle et al 28 | 97.8% | NR | NR |
| Community-based models | |||
| Guure et al 29 | 6.4% | Ever used/those who have heard of PrEP | FSWs who were willing to use PrEP had higher odds of ever taking compared with FSWs not willing to take PrEP (OR 43; CI: 2.93 to 150); FSWs who had screened for STIs had higher odds of taking PrEP than those who had never screened (OR 5.2; CI: 1.68 to 11.36). |
| Matambanadzo et al 30 | 33.7% | Enrolled/eligible | NR |
| Witte et al 31 | 55.2% | Enrolled/eligible, not on PrEP already | FSWs with greater social support (aOR 0.81; 95% CI: 0.05 to 0.66) were less likely to initiate, while those with high family stigma related to sex work (aOR 2.2; 95% CI: 1.15 to 4.22) were more likely to initiate PrEP. Decliners expressed inability to adhere to daily medication (16.4%), concerns about side effects (5%) and fear of stigma associated with HIV-positive status (3.8%). |
| Reza-Paul et al 32 | 99.2% | Enrolled/eligible | NR |
*Results not disaggregated for FSWs.
aOR, adjusted OR; FSWs, female sex workers; NR, not reported; PrEP, pre-exposure prophylaxis; RR, relative risk; STIs, sexually transmitted infections.
PrEP retention
Eight studies reported PrEP retention at 1 month and quarterly intervals according to refill schedules at health facilities21 24 25 27 28 30 32 33 (online supplemental table 2). Five studies21 24 25 27 28 reported facility model retention and three reported community model retention.30 32 33 Overall, the pooled proportion of month 6 retention was 76% (95% CI: 55% to 97%): 83% (95% CI: 73% to 91%) for facility models25 28 and 66% (95% CI: 15% to 100%)30 32 for community models (online supplemental figure 2). PrEP retention at 1 month was generally >80% except for three studies,21 28 30 and gradually decreased over time. However, three studies reported an initial increase and maintained high retention levels.21 24 32 Compared with younger FSWs (18–25 years), older FSWs were less likely to discontinue PrEP (HR 0.5; 95% CI: 0.2 to 0.9 for 26–35 years, HR 0.3; 95% CI: 0.2 to 0.7 for 36–45 years and HR 0.2; 95% CI: 0.1 to 0.5 for >45 years)25 (online supplemental table 2A). Reasons for PrEP discontinuation included moving out of town,7 25 returning to the country of origin,27 pregnancy,25 27 no longer doing sex work,7 24 not taking a daily pill,7 24 breast feeding, HIV seroconversion, desire to marry, partner’s request,27 serious injury or death,25 and being in police custody.24
PrEP adherence
Five studies reported PrEP adherence24 25 27 28 32 (online supplemental table 3), of which four studies reported facility models.24 25 27 28 The most common adherence measure was self-report.24 27 28 32 Other adherence measures were plasma tenofovir disoproxil fumarate levels24 25 32 and Medical Event Management System.25 Adherence after 7 days was mostly self-reported and increased from 71% in the 1st month to 75% by the 15th month. Non-condom use at the last sex act with a paying customer (aOR 0.07; 95% CI: 0.01 to 0.42) was associated with poor PrEP adherence. Other reasons associated with poor adherence included simply forgetting (20%), being too busy (14%) and running out of study pills (14%),25 as well as the duration of sex work, high intention to adhere to treatment,27 not interested in daily medication or no longer felt at risk21 (online supplemental table 3A).
Discussion
This systematic review summarised the pooled proportions of FSWs who initiated PrEP, remained engaged in care, and adhered to PrEP in SSA and other LMIC settings during the past decade, irrespective of whether PrEP was delivered through facility or community models. None of the included studies directly evaluated the impact of facility or community-based delivery models on FSW PrEP uptake, retention and adherence. This review corroborates evidence from earlier studies suggesting that current PrEP delivery methods in SSA may not fully address FSWs’ unique challenges, such as high mobility, intimate partner violence and stigma.10 34–36 These factors have a significant impact on PrEP adherence and retention. A review of PrEP studies found that PrEP uptake, retention and adherence were low in real-world settings, suggesting that oral PrEP adherence involves more than receiving a pill. Therefore, PrEP programmes should address context and population-specific adherence facilitators and barriers for FSWs.34
The heterogeneous composition of these models made it difficult to draw direct comparisons between facility-based and community-based PrEP delivery models. Thus, it was impossible to objectively evaluate which delivery platform best optimises PrEP initiation and continuation for FSWs in this setting. Several variations of infrastructural settings, providers and delivery channels were used for both community and facility-based delivery models in SSA and India, as there are currently no universally accepted guidelines for what should define a facility or community delivery model. Effective HIV prevention packages for FSWs should include combinations of biomedical, behavioural and structural interventions tailored to local contexts.37 38 In contrast, demonstration projects and clinical trial studies demonstrated high PrEP uptake, retention and adherence.39–45 The comparatively lower uptake, retention and adherence observed in real-world settings than reported by clinical trials and demonstration projects may be due to inconvenient clinic hours, extended wait times at clinics, stigmatisation of sex work and discrimination in healthcare settings.5
Our systematic review is the first to evaluate PrEP uptake, retention and adherence among FSWs in SSA within community and facility delivery models. The main limitation of this review was the inability to compare facility and community delivery models directly. Some of the included studies focused on key populations in general and had very small sample sizes of FSWs. Furthermore, this review was limited to evaluating oral PrEP uptake, retention and adherence for FSWs who used either community or facility PrEP delivery models. No study in our review compared outcomes across facility versus community models. Finally, the included studies did not address long-term PrEP continuation, HIV drug resistance or sexual behaviours.
The findings of this systematic review suggest that a tailored PrEP delivery model for FSWs could improve PrEP uptake, adherence and retention by addressing FSW-specific barriers. Therefore, further research is necessary to conduct a needs assessment to determine the preferred PrEP delivery model for FSWs. Differentiated delivery models that address the needs of FSWs, such as tailored clinic hours that accommodate their mobility, multimonth drug refills, appointment spacing, peer delivery of PrEP refills and HIV/syphilis self-tests, peer support for adherence and retention in care, and sexual and reproductive health services, may enhance linkage and retention in PrEP care and decrease HIV incidence.30 46
Implementing strategies that address gender-based violence and offer mental health support can effectively promote PrEP continuation, alleviate the burden on health systems and enhance FSW participation in PrEP care.37 38 44 47 The WHO recommends the implementation of the following interventions for sex workers: (a) HIV prevention methods (condoms, PrEP), (b) harm reduction services (needle and syringe programmes, opioid substitution therapy, naloxone administration), (c) behavioural interventions, (d) testing for HIV and other sexually transmitted infections, (e) HIV treatment and care, and (f) prevention and management of tuberculosis, hepatitis and mental health.9 An effective PrEP delivery model must prioritise addressing barriers to accessing care, such as HIV stigma resulting from the misidentification of PrEP as antiretroviral treatment, lack of awareness about its effectiveness, potential side effects, geographical distance from clinics and ensuring appropriate monitoring for PrEP adherence as well as HIV self-tests.10 34 35 38 Future studies should focus on determining if providing choice of delivery models increases PrEP uptake and retention for FSWs.
Supplementary Material
Footnotes
@ivansegy47, @Kevin_O_Ojiambo
Contributors: RM, JN, FCS, PK, JNK, AKi, CK, AKa, MK and AM were primarily responsible for the study design. KOO and IS led the screening and data extraction with oversight from RM. RM and IS prepared the first draft of the manuscript. RM, IS and OK prepared the tables and figures. RM, IS and AM contributed to data interpretation. RM and AM contributed to the main content of the manuscript. AM provided critical revisions to the manuscript. All authors read, revised and approved the final manuscript. RM accepts full responsibility for the work and conduct of the study, has access to the data and controlled the decision to publish.
Funding: Research reported in this publication was supported by the Fogarty International Center, National Institute of Alcohol Abuse and Alcoholism, National Institute of Mental Health, of the National Institutes of Health under award number D43TW011304.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Competing interests: None declared.
Patient and public involvement: The PrEP technical team at the School of Medicine, Makerere University, Uganda provided feedback on the review protocal and analysis. FSW were involved in a qualitative study, and the Ugandan Ministry of Health may ultimately consider their stated preferences while developing PrEP delivery guidelines.
Provenance and peer review: Not commissioned; externally peer reviewed.
Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Data availability statement
No data are available.
Ethics statements
Patient consent for publication
Not applicable.
Ethics approval
This systematic review had no contact with human and other materials.
References
- 1. AIDS . UNAIDS Global AIDS Update 2022. Geneva: Joint United Nations Programme on HIV. 2022. [Google Scholar]
- 2. Simbayi LC, Moyo S, van Heerden A, et al. Global HIV efforts need to focus on key populations in Lmics. Lancet 2021;398:2213–5. 10.1016/S0140-6736(21)02692-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Sheth AN, Rolle CP, Gandhi M. HIV pre-exposure prophylaxis for women. J Virus Erad 2016;2:149–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Vojnov L, Venter WDF. Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV. Lancet Glob Health 2022;10:e1549–50. 10.1016/S2214-109X(22)00408-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. O’Malley G, Barnabee G, Mugwanya K. Scaling-up prep delivery in sub-Saharan Africa: what can we learn from the scale-up of ART Curr HIV/AIDS Rep 2019;16:141–50. 10.1007/s11904-019-00437-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Behanzin L, Guedou FA, Geraldo N, et al. Prep and early antiretroviral therapy demonstration project: challenges to ensure follow-up and adherence among female sex workers in Cotonou, Benin. In: Book Prep and Early Antiretroviral Therapy Demonstration Project: Challenges to Ensure Follow-up and Adherence among Female Sex Workers in Cotonou, Benin (MARY ANN LIEBERT, INC 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA, 2016, Edn.). [Google Scholar]
- 7. Mboup A, Béhanzin L, Guédou FA, et al. Early antiretroviral therapy and daily Pre‐Exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. J Int AIDS Soc 2018;21:e25208. 10.1002/jia2.25208 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Eakle R, Bourne A, Mbogua J, et al. Exploring acceptability of oral prep prior to implementation among female sex workers in South Africa. J Int AIDS Soc 2018;21:e25081. 10.1002/jia2.25081 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. World Health Organization . Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance: technical brief. 2022.
- 10. Vanhamel J, Rotsaert A, Reyniers T, et al. The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a Scoping review. BMC Health Serv Res 2020;20:704:704. 10.1186/s12913-020-05568-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Ramraj T, Chirinda W, Jonas K, et al. Service delivery models that promote linkages to prep for adolescent girls and young women and men in sub-Saharan Africa: a Scoping review. BMJ Open 2023;13:e061503. 10.1136/bmjopen-2022-061503 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Ekwunife OI, Ejie IL, Okelu V, et al. Interventions to increase the uptake and continuation of pre-exposure prophylaxis (prep) by adolescent girls and young women at high risk of HIV in low-income and middle-income countries: a Scoping review. BMJ Glob Health 2022;7:e009474. 10.1136/bmjgh-2022-009474 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:S1743-9191(21)00040-6. 10.1016/j.ijsu.2021.105906 [DOI] [PubMed] [Google Scholar]
- 14. Tricco AC, Tetzlaff J, Moher D. Knowledge synthesis. Knowledge Translation in Health Care 2013;29–49. 10.1002/9781118413555 [DOI] [Google Scholar]
- 15. Prictor M, Hill S. Cochrane consumers and communication review group: leading the field on health communication evidence. J Evid Based Med 2013;6:216–20. 10.1111/jebm.12066 [DOI] [PubMed] [Google Scholar]
- 16. Jüni P, Loke Y, Pigott T, et al. Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance. Br Med J 2016;355:i4919. 10.1136/bmj.i4919 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for Synthesisers of evidence. BMC Med Res Methodol 2021;21:189. 10.1186/s12874-021-01381-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc 2018;16:195–203. 10.1097/XEB.0000000000000141 [DOI] [PubMed] [Google Scholar]
- 19. Hensen B, Machingura F, Busza J, et al. How can we support the use of oral prep among young women who sell sex? A prep Cascade analysis. J Acquir Immune Defic Syndr 2021;88:45–56. 10.1097/QAI.0000000000002733 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Cowan FM, Davey C, Fearon E, et al. Targeted combination prevention to support female sex workers in Zimbabwe Accessing and adhering to Antiretrovirals for treatment and prevention of HIV (SAPPH-ire): a cluster-randomised trial. Lancet HIV 2018;5:e417–26. 10.1016/S2352-3018(18)30111-5 [DOI] [PubMed] [Google Scholar]
- 21. Franks J, Teasdale C, Olsen H, et al. Prep for key populations: results from the first prep demonstration project in the Democratic Republic of the Congo. AIDS Care 2022;34:359–62. 10.1080/09540121.2021.1969332 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Leis M, McDermott M, Koziarz A, et al. Intimate partner and client-perpetrated violence are associated with reduced HIV pre-exposure prophylaxis (prep) uptake, depression and generalized anxiety in a cross-sectional study of female sex workers from Nairobi, Kenya. J Int AIDS Soc 2021;24:e25711. 10.1002/jia2.25711 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Pillay D, Stankevitz K, Lanham M, et al. Factors influencing uptake, continuation, and discontinuation of oral prep among clients at sex worker and MSM facilities in South Africa. PLoS One 2020;15:e0228620. 10.1371/journal.pone.0228620 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Jana S, Ray P, Roy S, et al. Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. Int J STD AIDS 2021;32:638–47. 10.1177/0956462420983992 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Sarr M, Gueye D, Mboup A, et al. Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. Int J STD AIDS 2020;31:1063–72. 10.1177/0956462420943704 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Kagaayi J, Batte J, Nakawooya H, et al. Uptake and retention on HIV Pre‐Exposure prophylaxis among key and priority populations in South‐Central Uganda. J Int AIDS Soc 2020;23:e25588. 10.1002/jia2.25588 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Mboup A, Béhanzin L, Guédou FA, et al. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study. J Int AIDS Soc 2018;21:e25208. 10.1002/jia2.25208 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Eakle R, Gomez GB, Naicker N, et al. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: results from a prospective observational demonstration project. PLoS Med 2017;14:e1002444. 10.1371/journal.pmed.1002444 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Guure C, Afagbedzi S, Torpey K. Willingness to take and ever use of pre-exposure prophylaxis among female sex workers in Ghana. Medicine (Baltimore) 2022;101:e28798. 10.1097/MD.0000000000028798 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Matambanadzo P, Busza J, Mafaune H, et al. It went through the roof": an observation study exploring the rise in prep uptake among Zimbabwean female sex workers in response to adaptations during COVID-19. J Int AIDS Soc 2021;24 Suppl 6:e25813. 10.1002/jia2.25813 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Witte SS, Filippone P, Ssewamala FM, et al. Prep acceptability and initiation among women engaged in sex work in Uganda: implications for HIV prevention. EClinicalMedicine 2022;44:101278. 10.1016/j.eclinm.2022.101278 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Reza-Paul S, Lazarus L, Maiya R, et al. The Ashodaya prep project: lessons and implications for Scaling up prep from a community-led demonstration project among female sex workers in Mysore, India. Glob Public Health 2020;15:889–904. 10.1080/17441692.2020.1724316 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Little K, Hanif H, Anderson S, et al. Preferences for Implantable pre-exposure prophylaxis products among adolescent girls, young women, and female sex workers in South Africa. In: Book Preferences for implantable pre-exposure prophylaxis products among adolescent girls, young women, and female sex workers in South Africa (JOHN WILEY & SONS LTD THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W …, 2021, edn.). [Google Scholar]
- 34. Mugo NR, Ngure K, Kiragu M, et al. Prep for Africa: what we have learnt and what is needed to move to program implementation. Curr Opin HIV AIDS 2016;11:80. 10.1097/COH.0000000000000224 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Jonas A, Patel SV, Katuta F, et al. HIV prevalence, risk factors for infection, and uptake of prevention, testing, and treatment among female sex workers in Namibia. J Epidemiol Glob Health 2020;10:351–8. 10.2991/jegh.k.200603.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Vuylsteke BL, Ettiègne-Traore V, Anoma CK, et al. Assessment of the validity of and adherence to sexually transmitted infection Algorithms at a female sex worker clinic in Abidjan, Côte D'Ivoire. Sex Transm Dis 2003;30:284–91. 10.1097/00007435-200304000-00003 [DOI] [PubMed] [Google Scholar]
- 37. Bekker L-G, Johnson L, Cowan F, et al. Combination HIV prevention for female sex workers: what is the evidence? Lancet 2015;385:72–87. 10.1016/S0140-6736(14)60974-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Vuylsteke B, Semdé G, Auld AF, et al. Retention and risk factors for loss to follow-up of female and male sex workers on antiretroviral treatment in Ivory Coast: a retrospective cohort analysis. J Acquir Immune Defic Syndr 2015;68 Suppl 2:S99–106. 10.1097/QAI.0000000000000442 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in Heterosexual men and women. N Engl J Med 2012;367:399–410. 10.1056/NEJMoa1108524 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083–90. 10.1016/S0140-6736(13)61127-7 [DOI] [PubMed] [Google Scholar]
- 41. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and Transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014;14:820–9. 10.1016/S1473-3099(14)70847-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53–60. 10.1016/S0140-6736(15)00056-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Molina J-M, Capitant C, Spire B, et al. On-demand Preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237–46. 10.1056/NEJMoa1506273 [DOI] [PubMed] [Google Scholar]
- 44. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral Preexposure prophylaxis for Heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34. 10.1056/NEJMoa1110711 [DOI] [PubMed] [Google Scholar]
- 45. Mujugira A, Nakyanzi A, Kasiita V, et al. HIV self-testing and oral pre-exposure prophylaxis are empowering for sex workers and their intimate partners: a qualitative study in Uganda. J Int AIDS Soc 2021;24:e25782. 10.1002/jia2.25782 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Mugo PM, Sanders EJ, Mutua G, et al. Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya. AIDS Behav 2015;19:794–801. 10.1007/s10461-014-0958-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Wanga V, Omollo V, Bukusi EA, et al. Uptake and impact of Facility‐Based HIV Self‐Testing on prep delivery: a pilot study among young women in Kisumu, Kenya. J Int AIDS Soc 2020;23:e25561. 10.1002/jia2.25561 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
bmjopen-2023-076545supp001.pdf (366.7KB, pdf)
bmjopen-2023-076545supp006.pdf (125.4KB, pdf)
bmjopen-2023-076545supp005.pdf (127.4KB, pdf)
bmjopen-2023-076545supp003.pdf (139.1KB, pdf)
bmjopen-2023-076545supp002.pdf (328.1KB, pdf)
bmjopen-2023-076545supp004.pdf (139.2KB, pdf)
Data Availability Statement
No data are available.

